Gender alone offers no survival advantage in humans following trauma. However, male gender does predict increased morbidity, specifically ventilator-associated pneumonia (VAP). Previous work has shown that despite lower incidence of VAP, females with VAP have increased mortality. The purposes of this study were to evaluate the impact of VAP and gender on outcome and to determine which characteristics of severe VAP predict mortality in trauma patients.
V entilator-associated pneumonia (VAP) is the most common pulmonary complication in trauma and the leading cause of death associated with nosocomial infections. 1, 2 The reported incidence of VAP in trauma patients ranges from 4% to 87%.
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Previous work identified male gender as an independent risk factor for both intensive care unit (ICU)Yacquired pneumonia and VAP. 6Y8 Kollef et al. 9 confirmed that male gender was an independent predictor of VAP in a prospective cohort study of 521 ICU patients requiring mechanical ventilation for more than 12 hours. Rello et al. 10 examined 842 patients who developed VAP and documented a significantly greater incidence in men (male, 64.1%; female, 35.9%). Multiple logistic regression analysis confirmed that male gender was independently associated with the development of VAP. 10 Although female trauma patients have a lower incidence of postinjury pneumonia, previous work has demonstrated that they have a higher mortality risk when they did develop pneumonia. 7, 8 In fact, despite an overall lower rate of pneumonia, female patients who developed pneumonia demonstrated a higher mortality rate when compared with age-and Injury Severity Score (ISS)Ymatched male trauma patients. 7 Similarly, previous work at our institution confirmed that females developed VAP following blunt trauma at a lower rate but were at an increased risk for mortality when compared with males. 8 Although gender alone offers no survival advantage in humans following trauma, 7, 8, 11 male gender does predict increased morbidity, specifically with respect to VAP. As stated, previous work has shown that despite a lower incidence of VAP, females with VAP have increased mortality. However, the potential factors responsible for this gender-related effect have not been elucidated. Thus, the purposes of this study were to evaluate the impact of VAP and gender on outcome and to determine which characteristics of severe VAP predict mortality in trauma patients.
PATIENTS AND METHODS

Study Population and VAP Diagnosis and Management
Trauma Center in Memphis, Tennessee, during an 8-year period diagnosed with VAP were identified from a prospectively maintained VAP database. Data from the VAP database were merged with the trauma registry (NTRACS version 3.5, Digital) to compile the final database for this study. At our institution, the diagnosis of VAP is confirmed using a combination of clinical triggers and bronchoalveolar lavage (BAL). The clinical triggers for bronchoscopy with BAL include any three of the following: abnormal temperature (Q101-F or e96-F), abnormal blood leukocyte count (Q10,000 HL or e4,000 HL), macroscopically purulent sputum, and new or changing infiltrate on chest radiograph. BAL was performed only in the presence of clinical triggers. 5 CFU/mL or greater in the BAL effluent, the antibiotic therapy is tailored appropriately for the bacterial pneumonia based on results from culture and sensitivities, which typically return within 96 hours. The duration of definitive antibiotic therapy is based on a previously published clinical pathway used at our institution.
Definition of Severe VAP, Risk Factors, and Outcomes
For the purposes of this study, severe VAP episodes were defined as patients who had at least one of the following characteristics: patients who had multiple episodes of VAP (91 episode during the same admission, mVAP); patients who had at least one multidrug-resistant pathogen on quantitative culture that met the diagnostic threshold for VAP categorized as having multidrug-resistant (MDR) VAP; VAP diagnosed within 7 days of hospital admission caused by a nosocomial pathogen defined as early nosocomial VAP (eNVAP); patients who had more than one episode of VAP in which inadequate empiric antibiotic therapy (mIEAT) was instituted before final culture results revealed inadequate treatment; and patients with VAP diagnosed by polymicrobial organisms (poly). The main outcome for the study was in-hospital mortality.
Statistical Analysis
Categorical variables were compared using W 2 analysis, while continuous variables were compared using a Student's t test. Multivariable logistic regression was then used to determine independent predictors of in-hospital mortality for patients with VAP. Characteristics for severe episodes of VAP, age, Glasgow Coma Scale (GCS), ISS, admission base excess, and 24-hour transfusions were chosen as covariates for the regression model. The final multivariable model was constructed in backward stepwise fashion. Differences were considered significant when p G 0.05. SAS version 9.3 (Cary, NC) was used for all statistical analyses.
RESULTS
During the study period, there were 854 patients who developed VAP, 676 males (79%) and 178 females (21%). Mean values for age, ISS, chest Abbreviated Injury Scale (AIS) score, and GCS score were 43 years, 31, 3.0, and 9.0, respectively. The mean admission base excess was j5.0 mEq/L, and patients received a mean of 5.7 U of red blood cell (RBC) during their first 24 hours after injury. The overall incidence of VAP was 2.6% in females and 3.8% in males ( p = 0.001). Overall mortality was 17%. The incidence of severe VAP was 52%. Patients with severe VAP had a higher mortality compared with patients without severe VAP (22% vs. 11%, p G 0.001). Table 1 lists the patient characteristics by gender. With respect to age, admission GCS score, chest AIS score, and 24-hour RBC transfusions, males and females with VAP were similar. However, females with VAP had a significantly higher ISS (30 vs. 33, p = 0.04) as well as a lower admission base excess (j4.7 vs. j6.0, p = 0.02).
Outcomes by gender are demonstrated in Table 2 . There were no differences in ventilator-free days, ICU days, or hospital length of stay. However, females with VAP did have a significantly higher mortality compared with males with VAP (15% vs. 24%, p = 0.009). With respect to severe VAP, females had a higher incidence of severe episodes compared with males (49% vs. 61%, p = 0.005). Males with severe VAP had a higher mortality compared with males without severe VAP (19% vs. 11%, p = 0.007). Females with severe VAP had a higher mortality compared with females without severe VAP (31% vs. 12%, p = 0.003).
Patients were then analyzed according to characteristics that portend more severe episodes of VAP, namely, those with multiple episodes of VAP (mVAP), those with multidrug resistant organisms (MDR), those with early (within 7 days of ICU admission) VAP because of nosocomial organisms (eNVAP), those with multiple episodes of inadequate empiric antibiotic therapy (mIEAT), and those with VAP from polymicrobial organisms (poly) ( Table 3) . Females fared worse than males in all instances except mVAP. Females had more VAP caused by MDR and polymicrobial organisms, had a larger incidence of early nosocomial VAP, and more often had mIEAT. In-hospital mortality was then compared between males and females with and without each characteristic of severe VAP (Table 4) . Females with only a single episode of VAP during the same admission had a larger mortality compared with males with only a single episode (13% vs. 22%, p = 0.04). Furthermore, females with the development of early nosocomial VAP (43% vs. 74%, p = 0.03) or VAP from polymicrobial organisms (17% vs. 38%, p e 0.001) had a larger mortality compared with males with the same diagnosis.
After adjusting for age, GCS score, ISS, admission base excess, 24-hour transfusions, and each of the characteristics of severe VAP, multivariable logistic regression found age, admission base excess, 24-hour transfusions, and the development of eNVAP to be independently associated with mortality for females with VAP (Table 5) . This analysis was then repeated using males with VAP. After adjusting for age, GCS score, ISS, admission base excess, 24-hour transfusions, and each of the characteristics of severe VAP, multivariable logistic regression found age, admission base excess, VAP from MDR or poly, and mIEAT to be independently associated with mortality for males with VAP.
DISCUSSION
During the past two decades, there has been an increasing interest in examining gender-related outcomes in trauma patients. Sexual dimorphism in response to trauma, hemorrhage, and sepsis has been described in both animal and human studies, suggesting differences in immune function and response to injury and infection. 7,12Y18 This effect seems to be related to both the beneficial effect of estrogen and the deleterious effect of testosterone. Wichmann et al. 13 demonstrated that castration before trauma and hemorrhage in a murine model had beneficial effects on splenocyte function and interleukin 2 release. Angele et al.
14 then showed that androgen receptor blockade with flutamide improved survival and immune function in a murine model of sepsis and hemorrhage. These animal studies suggest that androgen depletion prevents or reverses immunosuppression after trauma and hemorrhage.
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In humans, the results of gender effect on morbidity and mortality in trauma patients has been less convincing. Mostafa et al. 19 reported higher mortality rates in male patients aged 15 years 45 years when compared with female patients (13.4% vs. 6.8%). However, there was no difference in mortality in patients older than 45 years. These data were collected in a relatively small number of patients (612) and were further limited by subset analysis. In 2001, Napolitano et al. 7 found no relationship between gender and mortality in a study of more than 18,000 patients. However, they did identify that males had a higher incidence of pneumonia without an increase in mortality. The female patients who developed pneumonia had 2.8 times to 5.6 times the risk of death compared with their male counterparts. On the contrary, Rappold et al. 20 found males and females to have similar rates of mortality, adult respiratory distress syndrome, pneumonia, and sepsis. In their study of 1,229 patients, overall mortality was 2.7% for females and 2.9% for their matched male counterparts. On subset analysis to include hypotension and head injury, hypotension and no head injury, no hypotension and head injury, and no hypotension and no head injury, they still found no difference in mortality or acute complication rate. Criticisms of their data included a lack of power for the subset analysis, questionable definitions of both adult respiratory distress syndrome and pneumonia, and low overall complication rate, indicating that the number of patients with complications was too small to detect significant differences. In two separate studies from our institution, one examining 17,584 patients and the other examining 35,706 patients, there was no mortality difference among male and female trauma patients. 8, 11 In both studies, the groups were stratified both by age and gender with no difference in mortality. However, an increased incidence of VAP was noted in men after blunt trauma (5.8% vs. 4.5% in the initial study; 5.1% vs. 3.9% in those age G 40 years and 9.7% vs. 5.4% in those age 9 50 years in the second study). Furthermore, despite a lower incidence of VAP, females with VAP had a higher mortality rate compared with males. 8, 11 Multiple studies have identified an increased incidence of pneumonia in male patients. Offner et al. 12 demonstrated that male gender was associated with increased risk of infection following trauma. Males were 1.58 times more likely to develop a major infection, defined as pneumonia, abdominal and pelvic abscess, wound infection requiring operative debridement, and meningitis compared with females.
The current data confirm previous data from this institution and others. 7,8,11,17,21Y23 Although females have a lower incidence of VAP (3.8% vs. 2.6%, p = 0.001), they have a higher mortality rate (15% vs. 24%, p = 0.009). The data show that this mortality difference may be related to the type of VAP that female patients acquire. When characteristics of severe VAP were analyzed, females fared worse than males in almost all examined categories. After controlling for age, GCS score, ISS, admission base excess, 24-hour transfusions, and each of the characteristics of severe VAP, the development of early nosocomial VAP was found to be independently associated with mortality for females with VAP. When the regression analysis was repeated for males with VAP, mortality was found to be independently associated with VAP from either MDR or poly and with mIEAT.
This study has several limitations worth discussing, including the retrospective nature of the study itself. Furthermore, females with VAP were shown to have a higher ISS and a lower admission base excess, which may be confounding factors leading to a higher mortality. Although the regression analysis was performed to account for these potential factors, the increased injury burden demonstrated in females with VAP conceivably augments the mortality discrepancy between males and females. In addition, none of the five characteristics of severe VAP (mVAP, MDR, eNVAP, mIEAT, and poly) are mutually exclusive. Therefore, some patients have more than one of these conditions, which may impact the overall analysis. Finally, there was a large discrepancy in the number of patients with VAP between males and females, which certainly may limit the power of our analysis for females with VAP.
Despite a lower incidence of VAP, female trauma patients are at an increased risk of death after developing VAP compared with males. The pathophysiology of this phenomenon remains unproven. Nevertheless, it is clear that females are more likely to develop poly, MDR, mIEAT, and, most importantly, eNVAP. Potential directions for research will help identify the early nosocomial pathogens that are leading to higher mortality rates in female patients, which will likely lead to changes in our empiric regimen. When determining empiric antibiotic regimens, perhaps gender-specific antibiograms should be considered to cover eNVAP. Future investigations should explore the gender-related differences in trauma patients who develop pneumonia so that gender-specific treatments can be identified and implemented.
